sumatriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives	2543	103628-46-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: GR43175 GR 43175 sumatriptan sumatriptan succinate	A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS. Molecular weight: 295.40 Formula: C14H21N3O2S CLOGP: 0.74 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 65.20 ALOGS: -3.37 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

GR43175
GR 43175
sumatriptan
sumatriptan succinate

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Molecular weight: 295.40
Formula: C14H21N3O2S
CLOGP: 0.74
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 65.20
ALOGS: -3.37
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	N
50	mg	O
6	mg	P
25	mg	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	21.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	22 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.68 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	14 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.83 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1992	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	4103.62	11.46	911	45263	3671	56242222
Migraine	1094.57	11.46	751	45423	86046	56159847
Product dose omission issue	1052.84	11.46	1051	45123	203702	56042191
Application site erythema	566.64	11.46	192	45982	4408	56241485
Product quality issue	507.34	11.46	319	45855	31417	56214476
Application site burn	379.94	11.46	95	46079	692	56245201
Device deployment issue	334.31	11.46	122	46052	3502	56242391
Application site pain	328.61	11.46	123	46051	3797	56242096
Device malfunction	327.09	11.46	189	45985	15947	56229946
Application site discolouration	266.63	11.46	71	46103	681	56245212
Device issue	256.73	11.46	179	45995	20927	56224966
Application site paraesthesia	193.47	11.46	36	46138	39	56245854
Headache	146.92	11.46	869	45305	558175	55687718
Rheumatoid arthritis	145.60	11.46	66	46108	382538	55863355
Accidental exposure to product	145.51	11.46	137	46037	24510	56221383
Application site urticaria	138.40	11.46	34	46140	228	56245665
Application site rash	132.97	11.46	56	46118	2367	56243526
Medication overuse headache	125.51	11.46	39	46135	672	56245221
Application site irritation	124.61	11.46	48	46126	1604	56244289
Colitis ischaemic	117.21	11.46	83	46091	9937	56235956
Application site warmth	115.17	11.46	27	46147	144	56245749
Application site pruritus	111.53	11.46	57	46117	3762	56242131
Arteriospasm coronary	96.66	11.46	51	46123	3596	56242297
Anxiety	95.16	11.46	361	45813	192811	56053082
Glossodynia	92.52	11.46	9	46165	152449	56093444
Needle issue	89.96	11.46	67	46107	8671	56237222
Death	89.43	11.46	89	46085	341337	55904556
Injection site pain	86.39	11.46	251	45923	116867	56129026
Application site scar	82.89	11.46	22	46152	208	56245685
Systemic lupus erythematosus	82.11	11.46	23	46151	180055	56065838
Application site vesicles	79.79	11.46	33	46141	1332	56244561
Paraesthesia	77.13	11.46	259	45915	130255	56115638
Arthropathy	76.91	11.46	34	46140	200241	56045652
Injection site haemorrhage	75.29	11.46	92	46082	22109	56223784
Throat tightness	73.00	11.46	91	46083	22316	56223577
Wound	72.76	11.46	13	46161	138791	56107102
Application site swelling	71.66	11.46	24	46150	530	56245363
Contraindicated product administered	70.93	11.46	32	46142	186254	56059639
Product substitution issue	69.17	11.46	72	46102	14527	56231366
Infusion related reaction	69.10	11.46	43	46131	208888	56037005
Reversible cerebral vasoconstriction syndrome	68.03	11.46	35	46139	2342	56243551
IIIrd nerve paresis	67.60	11.46	17	46157	127	56245766
Wrong technique in product usage process	67.36	11.46	148	46026	58020	56187873
Device power source issue	65.26	11.46	22	46152	496	56245397
Muscle twitching	64.53	11.46	73	46101	16169	56229724
Treatment failure	63.73	11.46	30	46144	170362	56075531
Drug ineffective	63.69	11.46	1081	45093	917908	55327985
Product complaint	63.03	11.46	62	46112	11698	56234195
Depression	62.64	11.46	303	45871	179814	56066079
Cerebral vasoconstriction	62.02	11.46	26	46148	1086	56244807
Acute kidney injury	61.57	11.46	64	46110	240699	56005194
Serotonin syndrome	59.69	11.46	90	46084	26400	56219493
Coronary artery dissection	56.56	11.46	22	46152	755	56245138
Application site exfoliation	56.28	11.46	18	46156	342	56245551
Anaemia	55.94	11.46	83	46091	267428	55978465
Product leakage	55.25	11.46	21	46153	676	56245217
Endometriosis	55.11	11.46	39	46135	4663	56241230
Application site dryness	55.05	11.46	15	46159	158	56245735
Concussion	54.81	11.46	49	46125	8197	56237696
Chest discomfort	53.86	11.46	191	45983	98666	56147227
Dizziness	53.78	11.46	507	45667	375633	55870260
Cholecystitis chronic	53.38	11.46	52	46122	9696	56236197
Abdominal discomfort	52.37	11.46	92	46082	277182	55968711
Joint swelling	52.20	11.46	99	46075	289701	55956192
Application site reaction	51.98	11.46	20	46154	666	56245227
Lower respiratory tract infection	51.67	11.46	15	46159	114779	56131114
Pituitary tumour benign	51.20	11.46	27	46147	1901	56243992
Post-traumatic neck syndrome	50.55	11.46	27	46147	1951	56243942
Injection site bruising	50.36	11.46	103	46071	38418	56207475
Emotional distress	49.29	11.46	88	46086	29675	56216218
Application site scab	48.98	11.46	14	46160	178	56245715
Somnambulism	47.90	11.46	37	46137	5055	56240838
Renal infarct	47.37	11.46	23	46151	1359	56244534
Hostility	46.81	11.46	25	46149	1806	56244087
Device leakage	46.63	11.46	40	46134	6335	56239558
Drug specific antibody	46.53	11.46	26	46148	2054	56243839
Alopecia	46.34	11.46	108	46066	293350	55952543
Swelling	45.77	11.46	79	46095	239692	56006201
Incorrect dose administered by device	45.65	11.46	32	46142	3768	56242125
Libido increased	45.47	11.46	22	46152	1290	56244603
Febrile neutropenia	45.34	11.46	15	46159	105530	56140363
Cardiac failure	44.53	11.46	7	46167	82086	56163807
Soft tissue injury	44.19	11.46	23	46151	1576	56244317
Neutropenia	42.76	11.46	40	46134	158127	56087766
Incorrect route of product administration	41.84	11.46	68	46106	21261	56224632
Expired product administered	40.67	11.46	35	46139	5567	56240326
Off label use	40.36	11.46	279	45895	555901	55689992
Hepatic enzyme increased	40.03	11.46	49	46125	171335	56074558
Application site inflammation	39.55	11.46	14	46160	367	56245526
Nightmare	39.09	11.46	58	46116	16768	56229125
Disease progression	38.57	11.46	19	46155	105154	56140739
Application site bruise	38.57	11.46	13	46161	293	56245600
Tension headache	38.54	11.46	26	46148	2877	56243016
Sternal fracture	38.44	11.46	23	46151	2067	56243826
Suicidal ideation	38.05	11.46	119	46055	57623	56188270
Synovitis	37.79	11.46	46	46128	161259	56084634
Hot flush	37.20	11.46	103	46071	46623	56199270
Feeling abnormal	36.93	11.46	211	45963	133391	56112502
Nausea	36.57	11.46	851	45323	763327	55482566
Angle closure glaucoma	36.05	11.46	22	46152	2049	56243844
Clonus	35.94	11.46	29	46145	4220	56241673
Hypotension	35.05	11.46	98	46076	250410	55995483
Peripheral swelling	34.98	11.46	89	46085	234637	56011256
Infection	34.63	11.46	70	46104	200136	56045757
Secondary adrenocortical insufficiency	34.20	11.46	18	46156	1262	56244631
Pre-existing condition improved	34.17	11.46	36	46138	7362	56238531
Product use issue	33.95	11.46	63	46111	185978	56059915
Atrial fibrillation	33.83	11.46	24	46150	108873	56137020
Pneumonia	33.70	11.46	196	45978	406902	55838991
Hypoaesthesia	33.11	11.46	214	45960	141277	56104616
General physical health deterioration	32.44	11.46	56	46118	169954	56075939
Dysgeusia	32.38	11.46	90	46084	40825	56205068
Muscle tightness	32.12	11.46	42	46132	10794	56235099
Renal impairment	32.08	11.46	13	46161	80700	56165193
Therapeutic response unexpected	31.63	11.46	53	46121	16991	56228902
Impaired healing	31.37	11.46	16	46158	86825	56159068
Chest pain	31.24	11.46	264	45910	189533	56056360
Pancytopenia	31.08	11.46	17	46157	88698	56157195
Haemoglobin decreased	30.63	11.46	39	46135	134098	56111795
Diarrhoea	29.84	11.46	358	45816	638149	55607744
Hyponatraemia	28.59	11.46	25	46149	102114	56143779
Interstitial lung disease	28.50	11.46	6	46168	57057	56188836
Device defective	28.48	11.46	17	46157	1521	56244372
Hyperkalaemia	28.36	11.46	4	46170	50861	56195032
Application site discomfort	28.18	11.46	11	46163	381	56245512
Drug-disease interaction	28.13	11.46	11	46163	383	56245510
Renal tubular acidosis	27.91	11.46	17	46157	1578	56244315
Application site erosion	27.80	11.46	9	46165	178	56245715
Stomatitis	27.71	11.46	35	46139	120775	56125118
Plasma cell myeloma	27.64	11.46	3	46171	46643	56199250
Platelet count decreased	27.47	11.46	28	46146	106355	56139538
Transient global amnesia	27.29	11.46	12	46162	564	56245329
Hyperprolactinaemia	26.83	11.46	23	46151	3638	56242255
Pharyngeal swelling	26.64	11.46	27	46147	5279	56240614
Cluster headache	26.31	11.46	12	46162	615	56245278
Poor quality sleep	26.25	11.46	50	46124	17705	56228188
Photophobia	25.99	11.46	47	46127	16003	56229890
Vasospasm	25.97	11.46	12	46162	634	56245259
Malignant neoplasm progression	25.93	11.46	14	46160	73573	56172320
Migraine without aura	25.77	11.46	10	46164	341	56245552
Rash	24.72	11.46	272	45902	492775	55753118
Palpitations	24.70	11.46	153	46021	99519	56146374
Somnolence	24.64	11.46	223	45951	163190	56082703
Gastrointestinal haemorrhage	24.57	11.46	16	46158	75935	56169958
Blood creatinine increased	24.48	11.46	18	46156	80173	56165720
Pleural effusion	23.82	11.46	21	46153	85459	56160434
Eyelid ptosis	23.71	11.46	28	46146	6491	56239402
Injection site laceration	23.68	11.46	7	46167	101	56245792
Drug hypersensitivity	23.51	11.46	336	45838	274869	55971024
Tremor	23.51	11.46	175	45999	120914	56124979
Narcolepsy	23.03	11.46	14	46160	1295	56244598
Middle insomnia	22.97	11.46	36	46138	10914	56234979
Oxygen saturation decreased	22.55	11.46	19	46155	79048	56166845
Sepsis	22.41	11.46	51	46123	139789	56106104
Application site papules	21.95	11.46	6	46168	64	56245829
Personality disorder	21.83	11.46	24	46150	5149	56240744
Vasoconstriction	21.67	11.46	10	46164	527	56245366
Hip arthroplasty	21.62	11.46	3	46171	38620	56207273
Vision blurred	21.61	11.46	129	46045	82814	56163079
Underdose	21.57	11.46	55	46119	23702	56222191
Irritability	21.38	11.46	63	46111	29525	56216368
Blood testosterone increased	20.88	11.46	7	46167	155	56245738
Septic shock	20.81	11.46	12	46162	60823	56185070
Post-traumatic stress disorder	20.81	11.46	22	46152	4516	56241377
Injection site injury	20.80	11.46	10	46164	578	56245315
Muscle spasms	20.47	11.46	187	45987	137184	56108709
Gastrooesophageal reflux disease	20.12	11.46	127	46047	83130	56162763
Dependence	19.86	11.46	15	46159	1982	56243911
Phonophobia	19.85	11.46	8	46166	302	56245591
Pyrexia	19.81	11.46	234	45940	418539	55827354
Neck pain	19.55	11.46	101	46073	61454	56184439
Migraine with aura	19.53	11.46	16	46158	2378	56243515
Cardiac failure congestive	19.51	11.46	26	46148	87694	56158199
Basilar migraine	19.47	11.46	5	46169	41	56245852
Product adhesion issue	19.27	11.46	21	46153	4462	56241431
Neonatal respiratory distress	19.02	11.46	8	46166	337	56245556
Large intestinal ulcer haemorrhage	18.96	11.46	6	46168	110	56245783
Renal failure	18.78	11.46	39	46135	110461	56135432
Biliary dyskinesia	18.58	11.46	16	46158	2547	56243346
Spleen congestion	18.57	11.46	6	46168	118	56245775
Sunburn	18.55	11.46	16	46158	2552	56243341
Cerebral venous thrombosis	18.21	11.46	14	46160	1899	56243994
Paraesthesia oral	18.13	11.46	38	46136	14411	56231482
Red blood cell sedimentation rate increased	17.98	11.46	4	46170	36619	56209274
Thrombocytopenia	17.79	11.46	55	46119	136169	56109724
Depressive symptom	17.74	11.46	18	46156	3523	56242370
Osteonecrosis of jaw	17.74	11.46	3	46171	33355	56212538
Incorrect product administration duration	17.70	11.46	31	46143	10295	56235598
Device use error	17.51	11.46	22	46152	5434	56240459
Decreased appetite	17.33	11.46	107	46067	219124	56026769
Complement factor C4 decreased	17.32	11.46	7	46167	266	56245627
Discomfort	17.29	11.46	59	46115	141702	56104191
Multiple organ dysfunction syndrome	17.23	11.46	11	46163	52759	56193134
Blister	17.21	11.46	40	46134	108847	56137046
Hyperhidrosis	17.15	11.46	134	46040	93954	56151939
Lactic acidosis	17.08	11.46	4	46170	35342	56210551
Complement factor C3 decreased	16.82	11.46	7	46167	287	56245606
Memory impairment	16.74	11.46	125	46049	86432	56159461
Cough	16.59	11.46	135	46039	259826	55986067
Seizure	16.50	11.46	166	46008	124953	56120940
Application site dermatitis	16.41	11.46	6	46168	173	56245720
Subclavian artery thrombosis	16.41	11.46	6	46168	173	56245720
Meningoradiculitis	16.38	11.46	5	46169	81	56245812
Sleep talking	16.33	11.46	10	46164	937	56244956
Drug dependence	16.30	11.46	48	46126	22485	56223408
Knee arthroplasty	16.21	11.46	8	46166	44251	56201642
International normalised ratio increased	16.07	11.46	8	46166	44033	56201860
Superior sagittal sinus thrombosis	16.03	11.46	9	46165	718	56245175
Bipolar disorder	16.01	11.46	25	46149	7555	56238338
Major depression	16.00	11.46	25	46149	7559	56238334
Hyperacusis	15.97	11.46	13	46161	1915	56243978
Transverse sinus thrombosis	15.81	11.46	8	46166	517	56245376
Gastrointestinal disorder	15.80	11.46	44	46130	112658	56133235
Maternal exposure during pregnancy	15.78	11.46	91	46083	189462	56056431
Injury	15.53	11.46	93	46081	59758	56186135
Burning sensation	15.53	11.46	80	46094	48616	56197277
Multiple sclerosis	15.36	11.46	54	46120	27748	56218145
Hyperreflexia	15.02	11.46	20	46154	5230	56240663
Injury associated with device	15.01	11.46	16	46158	3317	56242576
Lichen planus	14.78	11.46	13	46161	2129	56243764
Cerebral venous sinus thrombosis	14.75	11.46	12	46162	1766	56244127
Liver injury	14.68	11.46	8	46166	41840	56204053
Peripheral nerve injury	14.59	11.46	7	46167	403	56245490
Gallbladder disorder	14.58	11.46	39	46135	17295	56228598
Rash maculo-papular	14.51	11.46	3	46171	28904	56216989
Multiple sclerosis relapse	14.48	11.46	74	46100	44829	56201064
Nipple pain	14.39	11.46	6	46168	247	56245646
Drug effect less than expected	14.32	11.46	9	46165	883	56245010
Trismus	14.15	11.46	16	46158	3542	56242351
Bone marrow failure	14.07	11.46	3	46171	28283	56217610
Teratogenicity	14.04	11.46	6	46168	263	56245630
Pancreatic failure	14.02	11.46	9	46165	916	56244977
Withdrawal syndrome	14.00	11.46	40	46134	18422	56227471
Potassium wasting nephropathy	13.91	11.46	4	46170	52	56245841
Inflammation	13.86	11.46	22	46152	69049	56176844
Ischaemic cerebral infarction	13.83	11.46	10	46164	1236	56244657
Burns third degree	13.75	11.46	6	46168	277	56245616
Sensory disturbance	13.49	11.46	31	46143	12512	56233381
Gallbladder injury	13.45	11.46	10	46164	1290	56244603
Therapeutic response shortened	13.35	11.46	26	46148	9360	56236533
Slow speech	13.27	11.46	10	46164	1317	56244576
Pneumonia aspiration	13.24	11.46	5	46169	32406	56213487
Post viral fatigue syndrome	13.20	11.46	6	46168	305	56245588
Premature delivery	13.20	11.46	3	46171	27057	56218836
Deep vein thrombosis	13.13	11.46	108	46066	76869	56169024
Cholestasis	13.09	11.46	3	46171	26910	56218983
Hepatic function abnormal	13.04	11.46	6	46168	34552	56211341
Neoplasm progression	12.97	11.46	5	46169	32011	56213882
Meningitis aseptic	12.96	11.46	17	46157	4382	56241511
Influenza like illness	12.90	11.46	90	46084	60898	56184995
Toxicity to various agents	12.82	11.46	120	46054	224444	56021449
Cardio-respiratory arrest	12.71	11.46	16	46158	55305	56190588
Granulocyte count increased	12.41	11.46	7	46167	563	56245330
Hepatotoxicity	12.40	11.46	5	46169	31148	56214745
Pharyngeal oedema	12.31	11.46	31	46143	13254	56232639
Nasal discomfort	12.22	11.46	16	46158	4116	56241777
Melaena	12.18	11.46	4	46170	28286	56217607
Alanine aminotransferase increased	12.09	11.46	38	46136	93624	56152269
Chemical burn	12.07	11.46	6	46168	373	56245520
Swollen tongue	11.98	11.46	53	46121	30271	56215622
Ovarian neoplasm	11.97	11.46	8	46166	872	56245021
Blood HIV RNA increased	11.95	11.46	7	46167	605	56245288
Product packaging quantity issue	11.81	11.46	9	46165	1205	56244688
Ill-defined disorder	11.80	11.46	24	46150	68519	56177374
Flushing	11.77	11.46	98	46076	70002	56175891
Therapeutic product effect decreased	11.74	11.46	86	46088	169366	56076527
Oedema	11.47	11.46	32	46142	81888	56164005

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	983.18	17.99	199	7278	2056	31687811
Migraine	288.91	17.99	113	7364	14067	31675800
Product dose omission issue	237.32	17.99	197	7280	105389	31584478
Product quality issue	123.61	17.99	65	7412	16046	31673821
Headache	98.63	17.99	164	7313	183488	31506379
Device deployment issue	95.73	17.99	18	7459	120	31689747
Arteriospasm coronary	69.39	17.99	26	7451	2865	31687002
Cluster headache	61.77	17.99	16	7461	514	31689353
Device malfunction	61.56	17.99	34	7443	9232	31680635
Device issue	56.00	17.99	31	7446	8453	31681414
Serotonin syndrome	50.36	17.99	39	7438	18734	31671133
Throat tightness	47.83	17.99	27	7450	7642	31682225
IIIrd nerve paresis	44.89	17.99	9	7468	87	31689780
Accidental exposure to product	42.48	17.99	29	7448	11466	31678401
Hyperhidrosis	37.06	17.99	61	7416	67332	31622535
Injection site pain	35.01	17.99	42	7435	34592	31655275
Application site pain	32.28	17.99	13	7464	1736	31688131
Medication overuse headache	31.38	17.99	7	7470	117	31689750
Myofascial pain syndrome	29.54	17.99	8	7469	306	31689561
Drug ineffective	27.55	17.99	173	7304	395400	31294467
Application site burn	27.48	17.99	7	7470	210	31689657
Acute kidney injury	27.48	17.99	16	7461	279698	31410169
Xanthelasma	27.20	17.99	6	7471	95	31689772
Gastrointestinal tract irritation	26.87	17.99	7	7470	230	31689637
Anophthalmos	26.64	17.99	4	7473	4	31689863
Needle issue	26.13	17.99	16	7461	5257	31684610
Congenital genital malformation male	25.02	17.99	4	7473	8	31689859
Facial pain	24.27	17.99	11	7466	1960	31687907
Burns second degree	23.90	17.99	7	7470	357	31689510
Foetal malnutrition	23.88	17.99	5	7472	61	31689806
Autonomic dysreflexia	23.31	17.99	5	7472	69	31689798
Electrocardiogram ST segment elevation	22.76	17.99	14	7463	4637	31685230
Foetal exposure during pregnancy	22.45	17.99	37	7440	40839	31649028
Death	21.96	17.99	32	7445	360537	31329330
Chest pain	21.96	17.99	69	7408	116888	31572979
Capillaritis	21.38	17.99	5	7472	104	31689763
Paraesthesia	20.98	17.99	43	7434	56028	31633839
Muscle tightness	20.56	17.99	13	7464	4516	31685351
Application site erythema	20.42	17.99	10	7467	2119	31687748
Craniosynostosis	19.85	17.99	6	7471	341	31689526
Aphasia	19.85	17.99	24	7453	19907	31669960
Irritable bowel syndrome	19.47	17.99	11	7466	3117	31686750
Tobacco abuse	18.91	17.99	6	7471	401	31689466
Chest discomfort	18.63	17.99	38	7439	49331	31640536
Anaemia	18.53	17.99	14	7463	213508	31476359
Injection site haemorrhage	18.32	17.99	16	7461	9069	31680798

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	1336.42	12.29	329	39877	3385	70884853
Migraine	1151.10	12.29	635	39571	71603	70816635
Application site erythema	407.88	12.29	138	40068	4623	70883615
Product dose omission issue	325.15	12.29	500	39706	216968	70671270
Application site burn	286.92	12.29	71	40135	745	70887493
Application site pain	238.87	12.29	91	40115	4311	70883927
Product quality issue	233.56	12.29	169	40037	30392	70857846
Headache	217.06	12.29	771	39435	579634	70308604
Application site discolouration	195.39	12.29	51	40155	673	70887565
Application site paraesthesia	182.68	12.29	32	40174	37	70888201
Device malfunction	182.14	12.29	121	40085	18963	70869275
Arteriospasm coronary	150.97	12.29	72	40134	5952	70882286
Accidental exposure to product	144.68	12.29	123	40083	27928	70860310
Medication overuse headache	132.73	12.29	38	40168	721	70887517
IIIrd nerve paresis	118.60	12.29	26	40180	151	70888087
Throat tightness	117.48	12.29	104	40102	24918	70863320
Colitis ischaemic	112.15	12.29	80	40126	14057	70874181
Acute kidney injury	110.81	12.29	66	40140	474558	70413680
Anxiety	104.56	12.29	318	39888	220012	70668226
Application site pruritus	102.49	12.29	47	40159	3554	70884684
Application site warmth	101.09	12.29	23	40183	162	70888076
Application site irritation	100.76	12.29	37	40169	1580	70886658
Device deployment issue	98.68	12.29	43	40163	2881	70885357
Paraesthesia	95.90	12.29	237	39969	145300	70742938
Death	92.27	12.29	92	40114	509969	70378269
Application site urticaria	89.67	12.29	22	40184	222	70888016
Application site rash	89.48	12.29	36	40170	1973	70886265
Serotonin syndrome	85.10	12.29	112	40094	42002	70846236
Reversible cerebral vasoconstriction syndrome	82.60	12.29	37	40169	2648	70885590
Wrong technique in product usage process	79.50	12.29	141	40065	68557	70819681
Device issue	78.89	12.29	82	40124	23943	70864295
Anaemia	73.78	12.29	72	40134	403351	70484887
Endometriosis	73.02	12.29	36	40170	3200	70885038
Cluster headache	72.14	12.29	25	40181	900	70887338
Application site swelling	71.37	12.29	23	40183	659	70887579
Cerebral vasoconstriction	70.18	12.29	27	40179	1313	70886925
Application site scar	68.89	12.29	17	40189	176	70888062
Dizziness	68.69	12.29	474	39732	463667	70424571
Depression	66.88	12.29	256	39950	198718	70689520
Muscle twitching	65.69	12.29	68	40138	19759	70868479
Chest discomfort	65.10	12.29	186	40020	124195	70764043
Drug ineffective	60.59	12.29	804	39402	938948	69949290
Cardiac failure	59.79	12.29	6	40200	143535	70744703
Emotional distress	58.89	12.29	88	40118	37100	70851138
Injection site pain	58.77	12.29	173	40033	117446	70770792
Pituitary tumour benign	57.19	12.29	28	40178	2451	70885787
Rheumatoid arthritis	56.97	12.29	49	40157	291756	70596482
Post-traumatic neck syndrome	56.93	12.29	26	40180	1947	70886291
Application site vesicles	56.32	12.29	23	40183	1310	70886928
Incorrect route of product administration	55.92	12.29	72	40134	26420	70861818
Hot flush	53.82	12.29	99	40107	49485	70838753
Concussion	53.74	12.29	42	40164	8467	70879771
Febrile neutropenia	52.59	12.29	25	40181	204293	70683945
Cholecystitis chronic	52.23	12.29	43	40163	9333	70878905
Coronary artery dissection	51.76	12.29	20	40186	984	70887254
Hypoaesthesia	50.97	12.29	197	40009	153542	70734696
Soft tissue injury	50.65	12.29	23	40183	1699	70886539
Chest pain	50.58	12.29	278	39928	250982	70637256
Pneumonia	50.14	12.29	172	40034	596060	70292178
Nausea	49.94	12.29	717	39489	851371	70036867
Drug specific antibody	49.75	12.29	25	40181	2314	70885924
Hostility	47.67	12.29	24	40182	2231	70886007
Muscle tightness	47.61	12.29	45	40161	11717	70876521
Injection site haemorrhage	47.15	12.29	65	40141	25462	70862776
Neutropenia	46.84	12.29	46	40160	257110	70631128
Libido increased	45.80	12.29	22	40184	1847	70886391
Sepsis	45.40	12.29	43	40163	244502	70643736
Tension headache	45.05	12.29	27	40179	3534	70884704
Renal infarct	45.00	12.29	24	40182	2513	70885725
Application site exfoliation	44.80	12.29	14	40192	362	70887876
Application site dryness	44.67	12.29	12	40194	178	70888060
Sternal fracture	43.85	12.29	23	40183	2328	70885910
Disease progression	42.14	12.29	18	40188	156654	70731584
Product substitution issue	41.74	12.29	52	40154	18461	70869777
Renal failure	41.67	12.29	28	40178	189042	70699196
Infusion related reaction	41.24	12.29	31	40175	197503	70690735
Device power source issue	40.92	12.29	16	40190	813	70887425
Hyperkalaemia	40.60	12.29	6	40200	106585	70781653
Interstitial lung disease	39.63	12.29	6	40200	104679	70783559
Renal impairment	39.58	12.29	16	40190	143921	70744317
Hypotension	39.38	12.29	109	40097	404272	70483966
Injection site bruising	38.86	12.29	74	40132	37958	70850280
Pancytopenia	38.10	12.29	19	40187	151088	70737150
Treatment failure	38.07	12.29	17	40189	144125	70744113
Angle closure glaucoma	37.59	12.29	22	40184	2757	70885481
Platelet count decreased	37.16	12.29	28	40178	178194	70710044
Pericarditis	36.72	12.29	3	40203	84702	70803536
Hyponatraemia	36.23	12.29	23	40183	160064	70728174
Feeling abnormal	36.01	12.29	168	40038	142151	70746087
Clonus	35.45	12.29	29	40177	6239	70881999
Multiple organ dysfunction syndrome	35.25	12.29	9	40197	108506	70779732
Vision blurred	35.04	12.29	126	40080	94858	70793380
Thrombocytopenia	34.78	12.29	51	40155	239059	70649179
Atrial fibrillation	34.69	12.29	32	40174	184316	70703922
Application site inflammation	34.09	12.29	12	40194	453	70887785
Suicidal ideation	33.45	12.29	101	40105	69495	70818743
Glossodynia	32.64	12.29	5	40201	86482	70801756
Photophobia	32.23	12.29	46	40160	18604	70869634
Palpitations	31.98	12.29	136	40070	110617	70777621
Septic shock	31.65	12.29	12	40194	112246	70775992
Lower respiratory tract infection	31.49	12.29	12	40194	111901	70776337
Expired product administered	30.78	12.29	27	40179	6386	70881852
Drug hypersensitivity	30.78	12.29	254	39952	262205	70626033
Plasma cell myeloma	30.63	12.29	3	40203	73198	70815040
Wound	30.55	12.29	9	40197	98723	70789515
Nightmare	30.28	12.29	49	40157	22107	70866131
Application site scab	30.09	12.29	9	40197	200	70888038
Gastrointestinal haemorrhage	29.40	12.29	21	40185	137387	70750851
Blood creatinine increased	29.13	12.29	23	40183	142978	70745260
Injury	28.86	12.29	92	40114	65153	70823085
Pleural effusion	28.83	12.29	20	40186	132844	70755394
Pharyngeal swelling	28.66	12.29	26	40180	6427	70881811
Application site bruise	28.36	12.29	9	40197	245	70887993
Hyperprolactinaemia	28.34	12.29	22	40184	4391	70883847
Secondary adrenocortical insufficiency	28.23	12.29	18	40188	2629	70885609
Malignant neoplasm progression	28.23	12.29	17	40189	121722	70766516
Hyperhidrosis	28.07	12.29	148	40058	131438	70756800
Hepatic function abnormal	27.90	12.29	3	40203	67993	70820245
Haemoglobin decreased	27.69	12.29	46	40160	205113	70683125
Subclavian artery thrombosis	27.64	12.29	6	40200	33	70888205
Transient global amnesia	26.93	12.29	12	40194	848	70887390
Pyrexia	26.78	12.29	218	39988	606734	70281504
Product adhesion issue	26.51	12.29	17	40189	2507	70885731
Off label use	26.31	12.29	282	39924	742778	70145460
Personality disorder	25.91	12.29	23	40183	5525	70882713
Application site reaction	25.60	12.29	11	40195	712	70887526
Pain	25.58	12.29	499	39707	628317	70259921
Vasospasm	25.40	12.29	12	40194	971	70887267
Poor quality sleep	25.13	12.29	43	40163	20306	70867932
Electrocardiogram ST segment elevation	25.04	12.29	26	40180	7578	70880660
Application site discomfort	25.02	12.29	9	40197	362	70887876
Somnambulism	24.96	12.29	22	40184	5238	70883000
Dysgeusia	24.88	12.29	73	40133	49429	70838809
Product leakage	24.78	12.29	11	40195	770	70887468
Middle insomnia	24.78	12.29	35	40171	14018	70874220
Respiratory failure	24.52	12.29	36	40170	168699	70719539
Therapeutic response unexpected	24.48	12.29	40	40166	18191	70870047
Cerebral venous thrombosis	24.12	12.29	16	40190	2499	70885739
Incorrect dose administered by device	24.02	12.29	20	40186	4409	70883829
Device leakage	24.01	12.29	28	40178	9280	70878958
Memory impairment	23.89	12.29	110	40096	92531	70795707
Temperature intolerance	23.78	12.29	27	40179	8696	70879542
Cardiac failure congestive	23.77	12.29	25	40181	135432	70752806
Migraine without aura	23.75	12.29	8	40198	264	70887974
Muscle spasms	23.68	12.29	159	40047	153887	70734351
Infection	23.46	12.29	53	40153	210732	70677506
Vasoconstriction	23.18	12.29	10	40196	654	70887584
Phonophobia	22.76	12.29	9	40197	471	70887767
Product complaint	22.37	12.29	31	40175	12200	70876038
Gastrooesophageal reflux disease	22.06	12.29	106	40100	90733	70797505
Renal tubular acidosis	22.00	12.29	17	40189	3369	70884869
Insomnia	21.99	12.29	204	40002	217602	70670636
Drug dependence	21.67	12.29	58	40148	37263	70850975
Gallbladder disorder	21.31	12.29	37	40169	17675	70870563
Systemic lupus erythematosus	21.25	12.29	16	40190	101886	70786352
Tremor	21.20	12.29	156	40050	155468	70732770
Burning sensation	21.10	12.29	72	40134	52798	70835440
Neck pain	20.92	12.29	84	40122	66573	70821665
Head discomfort	20.87	12.29	31	40175	12992	70875246
Arthropathy	20.85	12.29	33	40173	150024	70738214
Myofascial pain syndrome	20.83	12.29	13	40193	1829	70886409
Irritability	20.79	12.29	58	40148	38167	70850071
General physical health deterioration	20.51	12.29	67	40139	235964	70652274
Pharyngeal oedema	20.49	12.29	34	40172	15662	70872576
Post-traumatic stress disorder	20.05	12.29	18	40188	4389	70883849
Pre-existing condition improved	19.98	12.29	19	40187	4983	70883255
Decreased appetite	19.85	12.29	97	40109	304683	70583555
Migraine with aura	19.83	12.29	14	40192	2418	70885820
Basilar migraine	19.67	12.29	5	40201	59	70888179
Paraesthesia oral	19.59	12.29	33	40173	15384	70872854
Application site papules	19.59	12.29	5	40201	60	70888178
Flushing	19.32	12.29	95	40111	82077	70806161
Burns second degree	19.31	12.29	10	40196	986	70887252
Contraindicated product administered	19.28	12.29	29	40177	134583	70753655
Impaired healing	19.28	12.29	9	40197	74365	70813873
Aphasia	19.14	12.29	61	40145	43188	70845050
International normalised ratio increased	19.09	12.29	11	40195	80715	70807523
Withdrawal syndrome	19.02	12.29	43	40163	24861	70863377
Complement factor C4 decreased	19.01	12.29	7	40199	301	70887937
Xanthelasma	18.89	12.29	6	40200	164	70888074
Hyperreflexia	18.56	12.29	22	40184	7420	70880818
Loss of consciousness	18.39	12.29	151	40055	155565	70732673
Facial pain	18.35	12.29	23	40183	8213	70880025
Visual impairment	18.31	12.29	92	40114	80158	70808080
Dependence	18.20	12.29	13	40193	2287	70885951
Blood pressure systolic increased	18.11	12.29	5	40201	57254	70830984
Epistaxis	17.93	12.29	19	40187	102608	70785630
Diarrhoea	17.79	12.29	325	39881	783016	70105222
Meningitis aseptic	17.72	12.29	20	40186	6399	70881839
Ovarian neoplasm	17.72	12.29	8	40198	583	70887655
Biliary dyskinesia	17.71	12.29	13	40193	2386	70885852
Complement factor C3 decreased	17.71	12.29	7	40199	366	70887872
Blood bilirubin increased	17.57	12.29	6	40200	59895	70828343
Transverse sinus thrombosis	17.33	12.29	8	40198	614	70887624
Application site erosion	17.23	12.29	6	40200	219	70888019
Hyperacusis	17.19	12.29	12	40194	2036	70886202
Sunburn	17.07	12.29	15	40191	3556	70884682
Peripheral coldness	17.07	12.29	30	40176	14470	70873768
Burns third degree	17.00	12.29	7	40199	407	70887831
Injection site erythema	16.92	12.29	84	40122	72840	70815398
Therapeutic product effect incomplete	16.80	12.29	121	40085	119761	70768477
Teratogenicity	16.78	12.29	6	40200	237	70888001
Multiple sclerosis relapse	16.66	12.29	58	40148	42959	70845279
Lactic acidosis	16.65	12.29	8	40198	65016	70823222
Body temperature increased	16.56	12.29	55	40151	39779	70848459
Superior sagittal sinus thrombosis	16.42	12.29	9	40197	995	70887243
Hepatic enzyme increased	16.25	12.29	41	40165	156949	70731289
Hormone level abnormal	16.23	12.29	11	40195	1779	70886459
Injection site laceration	16.12	12.29	5	40201	126	70888112
Eyelid ptosis	16.12	12.29	24	40182	10078	70878160
Bone marrow failure	16.04	12.29	4	40202	49006	70839232
Toxicity to various agents	16.03	12.29	139	40067	382033	70506205
Haematuria	16.01	12.29	8	40198	63565	70824673
Vertigo	15.86	12.29	74	40132	62569	70825669
Oxygen saturation decreased	15.80	12.29	26	40180	116403	70771835
Meningoradiculitis	15.42	12.29	5	40201	146	70888092
Pancreatic failure	15.35	12.29	10	40196	1514	70886724
Gallbladder injury	15.26	12.29	9	40197	1143	70887095
Swollen tongue	15.26	12.29	51	40155	36995	70851243
Post viral fatigue syndrome	15.19	12.29	6	40200	313	70887925
Joint swelling	15.12	12.29	83	40123	253128	70635110
Tinnitus	15.08	12.29	50	40156	36126	70852112
Large intestinal ulcer haemorrhage	15.07	12.29	6	40200	320	70887918
Cerebral venous sinus thrombosis	14.98	12.29	11	40195	2020	70886218
Gastrointestinal tract irritation	14.97	12.29	7	40199	553	70887685
Aspartate aminotransferase increased	14.89	12.29	31	40175	126947	70761291
Hypoglycaemia	14.84	12.29	19	40187	94345	70793893
Swelling face	14.83	12.29	73	40133	63091	70825147
Torsade de pointes	14.65	12.29	32	40174	18084	70870154
Pericardial effusion	14.49	12.29	3	40203	41773	70846465
Deep vein thrombosis	14.38	12.29	110	40096	110932	70777306
Incorrect disposal of product	14.31	12.29	8	40198	919	70887319
Cardio-respiratory arrest	14.11	12.29	22	40184	100655	70787583
Haemorrhage	14.11	12.29	16	40190	83799	70804439
Peripheral nerve injury	13.75	12.29	7	40199	666	70887572
Stomatitis	13.74	12.29	33	40173	128478	70759760
Injection site urticaria	13.60	12.29	24	40182	11614	70876624
Incorrect product administration duration	13.53	12.29	23	40183	10801	70877437
Injection site injury	13.50	12.29	7	40199	692	70887546
Device difficult to use	13.49	12.29	23	40183	10826	70877412
Cytomegalovirus infection	13.49	12.29	3	40203	39755	70848483
Panic attack	13.47	12.29	35	40171	22084	70866154
Bradycardia	13.32	12.29	32	40174	124583	70763655
Inflammation	13.26	12.29	15	40191	78650	70809588
Drug effect less than expected	13.17	12.29	8	40198	1072	70887166
Major depression	13.16	12.29	20	40186	8554	70879684
Product dispensing error	13.05	12.29	24	40182	11984	70876254
Neutrophil count decreased	12.96	12.29	17	40189	83539	70804699
Choking sensation	12.95	12.29	13	40193	3642	70884596
Lichen planus	12.83	12.29	11	40195	2524	70885714
Somnolence	12.74	12.29	182	40024	215424	70672814
Alanine aminotransferase increased	12.71	12.29	42	40164	147438	70740800
Trismus	12.61	12.29	15	40191	5076	70883162
Neoplasm progression	12.47	12.29	5	40201	45223	70843015
Product use issue	12.45	12.29	56	40150	179881	70708357
Hyperglycaemia	12.43	12.29	11	40195	64661	70823577
Depressive symptom	12.40	12.29	15	40191	5166	70883072
Capillaritis	12.39	12.29	5	40201	276	70887962
Eye pain	12.36	12.29	45	40161	34057	70854181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02CC01	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists
CHEBI has role	CHEBI:35941	serotonin agonists
FDA MoA	N0000175763	Serotonin 1b Receptor Agonists
FDA MoA	N0000175764	Serotonin 1d Receptor Agonists
FDA EPC	N0000175765	Serotonin-1b and Serotonin-1d Receptor Agonist
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D058825	Serotonin 5-HT1 Receptor Agonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D014662	Vasoconstrictor Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364
Cluster headache syndrome	indication	193031009
Tachyarrhythmia	contraindication	6285003
Alcoholism	contraindication	7200002
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Hemiplegic migraine	contraindication	59292006
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Gastrointestinal hemorrhage	contraindication	74474003
Vascular insufficiency of intestine	contraindication	82196007
Epilepsy	contraindication	84757009	DOID:1826
Prinzmetal angina	contraindication	87343002
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Angina pectoris	contraindication	194828000
Cerebrovascular accident	contraindication	230690007
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Esophageal dysmotility	contraindication	266434009	DOID:9192
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Cerebral ischemia	contraindication	287731003
Pregnancy, function	contraindication	289908002
Thromboembolic disorder	contraindication	371039008
Serotonin syndrome	contraindication	371089000
Cardiovascular event risk	contraindication	395112001
Peripheral vascular disease	contraindication	400047006
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Hypertensive urgency	contraindication	443482000
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.23	acidic
pKa2	13.42	acidic
pKa3	8.28	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8327844	Oct. 3, 2023	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	7975690	Aug. 18, 2025	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8590530	Sept. 15, 2025	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
500MG;EQ 85MG BASE	TREXIMET	CURRAX	N021926	April 15, 2008	RX	TABLET	ORAL	7332183	Oct. 2, 2025	TREATMENT OF MIGRAINE
60MG;EQ 10MG BASE	TREXIMET	CURRAX	N021926	May 14, 2015	DISCN	TABLET	ORAL	7332183	Oct. 2, 2025	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	8440631	May 9, 2026	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	7973058	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8155737	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8470853	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	9427578	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	ALSUMA	MERIDIAN MEDCL	N022377	June 29, 2010	DISCN	INJECTABLE	SUBCUTANEOUS	7811254	Aug. 26, 2027	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8875704	April 7, 2028	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8366600	April 21, 2029	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	10603305	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	11337962	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9610280	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9974770	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8983594	Nov. 19, 2030	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9211282	July 19, 2031	ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	9327114	Oct. 8, 2032	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10478574	Nov. 4, 2033	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	ZEMBRACE SYMTOUCH	UPSHER SMITH LABS	N208223	Jan. 28, 2016	RX	SOLUTION	SUBCUTANEOUS	10537554	Jan. 29, 2036	TREATMENT OF MIGRAINE
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	ZEMBRACE SYMTOUCH	UPSHER SMITH LABS	N208223	Jan. 28, 2016	RX	SOLUTION	SUBCUTANEOUS	11364224	Jan. 29, 2036	TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Ki	8.92	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	8.26	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		IC50	8.14	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN	ANTAGONIST	Ki	5.60	IUPHAR
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	ANTAGONIST	Ki	6	IUPHAR
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		IC50	8.03	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		IC50	6.30	CHEMBL
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN		Ki	7.59	CHEMBL
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		IC50	5.26	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.17	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.64	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.42	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	7.64	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.19	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	ANTAGONIST	Ki	6.60	IUPHAR
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_PIG		IC50	7.70	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_MOUSE		IC50	6.35	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_RAT		IC50	7.21	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	5.20	IUPHAR
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_GORGO		Ki	8.19	CHEMBL
5-hydroxytryptamine 1D receptor	Unclassified		Q8MI13_BOVIN		IC50	7.23	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR		5HT5A_MOUSE	AGONIST	Ki	4.80	IUPHAR

External reference:

ID	Source
4021050	VUID
N0000148514	NUI
D00451	KEGG_DRUG
103628-48-4	SECONDARY_CAS_RN
4020790	VANDF
4021050	VANDF
C0075632	UMLSCUI
CHEBI:10650	CHEBI
CHEMBL128	ChEMBL_ID
DB00669	DRUGBANK_ID
CHEMBL1201150	ChEMBL_ID
D018170	MESH_DESCRIPTOR_UI
5358	PUBCHEM_CID
54	IUPHAR_LIGAND_ID
6125	INN_ID
8R78F6L9VO	UNII
37418	RXNORM
158892	MMSL
166806	MMSL
25268	MMSL
31925	MMSL
5536	MMSL
d03160	MMSL
004044	NDDF
004045	NDDF
322822007	SNOMEDCT_US
395892000	SNOMEDCT_US
96215002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2013	INJECTION	4 mg	SUBCUTANEOUS	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2014	INJECTION	6 mg	SUBCUTANEOUS	ANDA	28 sections
SUMATRIPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9638	INJECTION	6 mg	SUBCUTANEOUS	ANDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0478	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0478	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0479	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0479	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0523	SPRAY	20 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0523	SPRAY	20 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0524	SPRAY	5 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0524	SPRAY	5 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0735	TABLET, FILM COATED	25 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0735	TABLET, FILM COATED	25 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0736	TABLET, FILM COATED	50 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0736	TABLET, FILM COATED	50 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0737	TABLET, FILM COATED	100 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0737	TABLET, FILM COATED	100 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0739	INJECTION	4 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0739	INJECTION	4 mg	SUBCUTANEOUS	NDA	28 sections
ZEMBRACE SYMTOUCH	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0809	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	NDA	31 sections
TOSYMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0812	SPRAY	10 mg	NASAL	NDA	31 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5630	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5630	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5631	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5631	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5632	TABLET, FILM COATED	100 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5632	TABLET, FILM COATED	100 mg	ORAL	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1818	SPRAY	5 mg	NASAL	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1859	SPRAY	20 mg	NASAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-300	TABLET, FILM COATED	100 mg	ORAL	NDA	13 sections